Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Identifying novel antigens for TCR T-cell therapy

David Apelian • 29 Apr 2022
General Updates
General Leukemia

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, discusses work he is involved with on the first minor histocompatibility antigen (miHA) platform to treat patients with high-risk leukemia undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). In addition, work is being done to identify novel shared antigens that can be targeted by T-cell receptor (TCR) T-cells before achieving a fully personalized treatment platform to treat patients. This interview was recorded virtually.

More from David Apelian

TCXpress™ vs CAR-T therapy & targeting leukemia with TCR T-cells
3:17
TCXpress™ vs CAR-T therapy & targeting leukemia with TCR T-cells
David Apelian • 29 Apr 2022
TCXpress™, a novel promising TCR platform
2:16
TCXpress™, a novel promising TCR platform
David Apelian • 29 Apr 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals